Syngene International posts results, proposes Rs 1.25 dividend

Syngene International Limited posted modest revenue growth but a sharp profit decline for FY 2025‑26, proposing a final dividend of Rs 1.25 per share while expanding its biologics capacity.

• Revenue rose to Rs 37.4 bn (+2.6% YoY) and Rs 34.2 bn standalone (+1.5%), yet net profit fell to Rs 3.17 bn (‑36% YoY) consolidated and Rs 3.05 bn (‑35% YoY) standalone, driving earnings per share down to Rs 7.87 from Rs 12.35.
• Cash & cash equivalents dropped to Rs 2.29 bn from Rs 3.67 bn, with operating cash flow slipping to Rs 9.15 bn (down from Rs 11.68 bn YoY); investing and financing activities generated net outflows of Rs 8.60 bn and Rs 2.15 bn, respectively.
• The board approved a final dividend of Rs 1.25 per share (record date 26 June 2026) and appointed S.R. Batliboi & Associates LLP as statutory auditor through 2031.
• Strategic moves include integrating the US biologics site to lift single‑use bioreactor capacity to 50,000 L and securing a new drug‑substance production line and bonded‑warehouse license for the Bangalore facility; a labour‑code‑driven gratuity credit of Rs 229 mn (standalone) / Rs 244 mn (consolidated) partially offset earlier exceptional expenses.